Waltham, MA, United States of America

Kenneth Duncan

USPTO Granted Patents = 2 

Average Co-Inventor Count = 8.2

ph-index = 1

Forward Citations = 5(Granted Patents)


Location History:

  • Cambusbarron, GB (2011)
  • Waltham, MA (US) (2013)

Company Filing History:


Years Active: 2011-2013

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations by Kenneth Duncan

Introduction

Kenneth Duncan is an accomplished inventor based in Waltham, MA (US). He has made significant contributions to the field of pharmaceuticals, particularly through his innovative compounds and their therapeutic applications. With a total of 2 patents, Duncan's work is focused on addressing various medical disorders.

Latest Patents

Duncan's latest patents include the development of Pyrimidin-4-yl-3, 4-dihydro-2H-pyrrolo [1,2A] pyrazin-1-one compounds. This invention relates to compounds of formula (I), or pharmaceutically acceptable salts thereof, which have potential applications in treating proliferative disorders, viral disorders, and strokes. Another notable patent is for Pyrimidin-4-yl-3, 4-thione compounds, which also have therapeutic uses in treating conditions such as alopecia and diabetes.

Career Highlights

Kenneth Duncan is currently associated with Cyclacel Limited, a company known for its focus on innovative cancer therapies. His work at Cyclacel has allowed him to explore and develop new pharmaceutical compounds that can significantly impact patient care.

Collaborations

Duncan collaborates with talented professionals in his field, including Janice McLachlan and Daniella I Zheleva. These collaborations enhance the research and development efforts at Cyclacel Limited, fostering an environment of innovation.

Conclusion

Kenneth Duncan's contributions to pharmaceutical innovations demonstrate his commitment to improving healthcare through science. His patents reflect a dedication to addressing critical medical challenges, making him a notable figure in the field of invention.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…